1-3 of 3
William Olson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract IA012: REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy

Jiaxi Wu, Nicolin Bloch, Aaron Chang, Ramandeep Bhavsar, Qingqing Wang, Supriya Patel, Vidur Garg, Hassan Shakil, Michael Amatulli, Drew Dudgeon, Yuetian Yan, Shunhai Wang, Willy Ramos, Pamela Krueger, Kristin Vazzana, Alison Crawford, Jacqueline Idun, Corinne Decker, David DiLillo, Samira Chandwani, Tammy Huang, Jessica Kirshner, Chungguang Guo, Lynn Macdonald, Erica Ullman, Aynur Hermann, William Olson, Samuel Davis, John Lin, Eric Smith, Tong Zhang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): IA012.
https://doi.org/10.1158/1535-7163.TARG-23-IA012
Published: 01 December 2023
View article titled, Abstract IA012: REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy
Journal Articles

Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice

Elena Burova, Aynur Hermann, Janelle Waite, Terra Potocky, Venus Lai, Seongwon Hong, Matt Liu, Omaira Allbritton, Amy Woodruff, Qi Wu, Amanda D’Orvilliers, Elena Garnova, Ashique Rafique, William Poueymirou, Joel Martin, Tammy Huang, Dimitris Skokos, Joel Kantrowitz, Jon Popke, Markus Mohrs, Douglas MacDonald, Ella Ioffe, William Olson, Israel Lowy, Andrew Murphy, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (5): 861–870.
https://doi.org/10.1158/1535-7163.MCT-16-0665
Published: 02 May 2017
View article titled, Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <em>PD-1</em> Knock-In Mice
Open the PDF for Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <em>PD-1</em> Knock-In Mice in another window
Includes: Supplementary data
Journal Articles

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, Nithya Thambi, Andres E. Perez Bay, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (4): 681–693.
https://doi.org/10.1158/1535-7163.MCT-16-0658
Published: 02 April 2017
View article titled, Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Open the PDF for Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs in another window
Includes: Supplementary data